Search clinical trials for: azacitidine lenalidomide

Total 1849 results

Groupe Francophone des Myelodysplasies
Celgene

Completed

A Study of Azacitidine in Myelodysplastic Syndrome (MDS) Associated to Systemic Auto-immune and Inflammatory Disorders

MDS | Systemic Autoimmune Diseases

France
Julie Dawson

Completed

RCT to Investigate if Prostaglandin Analogue Drops Increase the Risk of Cystoid Macular Oedema After Cataract Surgery. (CMO)

Open Angle Glaucoma and Cataract

United Kingdom
Celgene

Completed

An Extension to Study AZA PH GL 2003 CL 001 Allowing for Continuation of Azacitidine Treatment in Patients With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

Italy, United Kingdom, Germany, Australia, Bulgaria, France, Greece, Hungary, Netherlands, Poland, Spain
Celgene

Completed

Study of Azacitidine to Evaluate Safety and Effectiveness for Chinese Patients With Higher Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS)

China
Boehringer Ingelheim

Terminated

Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML

Myelodysplastic Syndromes | Leukemia, Myelomonocytic, Chronic

France, Germany
Boehringer Ingelheim

Terminated

Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

Japan
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT)

Leukemia | Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center

Recruiting

Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
University of California, San Diego

Completed

Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome

CLL | Richter's Syndrome

United States
Peter MacCallum Cancer Centre, Australia

Completed

Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma (EpiBrentlen)

Hodgkin Lymphoma | Lymphoma, T-Cell, Cutaneous | Lymphoma, T-Cell, Peripheral

Australia
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Terminated

Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Chidamide Combined With Azacitidine and Mitoxantrone Liposome in the Treatment of Relapsed/Refractory (nTFHL)

T Cell Lymphoma
Chinese PLA General Hospital
The General Hospital of Western Theater Command; First Hospital of China Medical... and other collaborators

Recruiting

Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Relapsed/Refractory Acute Myeloid Leukemia

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated (ALIVE)

Acute Myeloid Leukemia (AML)

China
University Hospital Regensburg
Celgene; Anticancer Fund, Belgium

Terminated

Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML (AML-ViVA)

Acute Myeloid Leukemia

Germany
Celgene

Completed

Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer (abound2L+)

Carcinoma, Non-Small-Cell Lung

United States, Canada, France, Germany, Italy, Spain, United Kingdom
Acute Leukemia French Association
Assistance Publique - Hôpitaux de Paris

Withdrawn

ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML) (ALFA-0703)

Acute Myeloid Leukemia

France
The Second Affiliated Hospital of Kunming Medical...

Not yet recruiting

Comparison of the Efficacy and Safety of Venetoclax in Combination With 3 Days Decitabine (DEC3-VEN) vs. Venetoclax in Combination With Azacitidine (VIALE-A) in the Treatment of Elderly Patients or Unfit, New-diagnosis Acute Myeloid Leukemia Patients

Acute Myeloid Leukemia | Decitabine | Venetoclax | Elderly AML Patients | Unfit, New-diagnosis AML

China
The Lymphoma Academic Research Organisation
Celgene

Active, not recruiting

Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL

Relapsed Angioimmunoblastic T-Cell Lymphoma | Refractory Angioimmunoblastic T-cell Lymphoma

France, Denmark, United Kingdom, Austria, Belgium
Millennium Pharmaceuticals, Inc.

Completed

A Study of Pevonedistat in Adult East Asian Participants

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

Japan, Taiwan, Korea, Republic of
Akeso

Recruiting

A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

Higher-risk Myelodysplastic Syndromes

United States, China
Guangzhou Lupeng Pharmaceutical Company LTD.

Recruiting

A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

China
Millennium Pharmaceuticals, Inc.

Completed

An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Chronic

United States, Israel, Spain, France, Ireland, Canada, Germany, Czechia, Italy, Netherlands, Belgium, Bulgaria
PETHEMA Foundation
Millennium Pharmaceuticals, Inc.; Dynamic Science S.L.

Active, not recruiting

Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy (PEVOLAM)

Leukemia, Myeloid, Acute

Spain, Portugal
Innovent Biologics (Suzhou) Co. Ltd.

Suspended

A Study Evaluating the Safety and Efficacy of IBI188 in Combination With AZA in Subjects With Newly Diagnosed MDS

MDS

United States
University of Ulm
Sunesis Pharmaceuticals

Completed

Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2

Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2)

Germany
GlaxoSmithKline
Parexel

Terminated

Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | Myelodysplastic Syndrome

United States, Spain
Santen Inc.

Completed

Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

Open-angle Glaucoma or Ocular Hypertension

United States
Asociación Andaluza de Hematología y Hemoterapia

Completed

Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia (ABRAZA)

Myelodysplastic Syndrome (MDS)

Spain
Kansas City Veteran Affairs Medical Center

Unknown

Trial With Azacitidine in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Not Eligible for Standard Induction Therapy

Acute Myeloid Leukemia | Elderly

United States
Incyte Biosciences Japan GK

Recruiting

To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) (J-MIND)

Diffuse Large B-cell Lymphoma | Non Hodgkins Lymphoma

Japan
Yale University
Peter MacCallum Cancer Centre, Australia

Terminated

An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study) (RID)

Multiple Myeloma | Hodgkin's Lymphoma | Mature T-cell Lymphoma

United States
Scripps Health
Bristol-Myers Squibb; Celgene Corporation

Withdrawn

A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia

Leukemia | Chronic Lymphocytic Leukemia
Therapeutic Advances in Childhood Leukemia Consortium
Gateway for Cancer Research

Completed

A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML

Lymphoblastic Leukemia, Acute, Childhood | Myelogenous Leukemia, Acute, Childhood

United States, Canada, Australia
Centre Hospitalier Universitaire, Amiens
Institut Bergonié; Centre Henri Becquerel; Saint-Louis Hospital, Paris, France; Henri Mondor University Hospital and other collaborators

Recruiting

Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma (Relyage)

Chemotherapy | Elderly | Diffuse Large B-Cell Lymphoma (DLBCL), Nos

France
Wuerzburg University Hospital
Celgene Corporation; ClinAssess GmbH

Active, not recruiting

Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance

Previously Untreated Symptomatic Multiple Myeloma

Germany
AB Science

Recruiting

AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory | Myelodysplastic Syndrome Acute Myeloid Leukemia

United States, Spain, France, Greece
University Health Network, Toronto

Recruiting

Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms

Myeloproliferative Neoplasm

Canada
Akeso

Recruiting

A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Edgewood Oncology Inc.

Recruiting

A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Amgen

Completed

AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic Leukemia | Higher Risk Myelodysplastic Syndrome

United States
Genentech, Inc.

Completed

A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy

Leukemia, Myeloid, Acute

United States, Canada
Celgene

Completed

AVIDA The Vidaza® (Azacitidine) Patient Registry (AVIDA)

Myelodysplastic Syndromes

United States
H. Lee Moffitt Cancer Center and Research Institute
Celgene Corporation

Completed

Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia (AML) in CR After Induction Chemotherapy

Leukemia

United States
National Taiwan University Hospital

Not yet recruiting

Demethylating Agent Azacitidine on Prevention of Acute Kidney Injury-chronic Kidney Disease Continuum

Acute Kidney Disease

Taiwan
University of Colorado, Denver
AbbVie

Recruiting

Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
Aprea Therapeutics

Completed

APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant

Acute Myeloid Leukemia or Myelodysplastic Syndromes

United States
Helsinn Healthcare SA

Terminated

A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Celgene

Completed

A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia.

Leukemia, Myeloid, Acute

Germany, Netherlands, Denmark
Celgene

Completed

Post Marketing Surveillance to Collect and Evaluate the Safety and Efficacy Information of Korean MDS Patients Treated With VIDAZA®, After Approval of Marketing Authorization for New Drug in Korea

Myelodysplastic Syndrome

Korea, Republic of

3

Subscribe